| Literature DB >> 30252956 |
Elisabetta Beneduce1, Alessandro Matte1, Luigia De Falco2, Serge Mbiandjeu1, Deborah Chiabrando3, Emanuela Tolosano3, Enrica Federti1, Sara Petrillo3, Narla Mohandas4, Angela Siciliano1, Wilson Babu1, Vijay Menon5, Saghi Ghaffari5, Achille Iolascon2, Lucia De Franceschi1.
1. Department of Medicine, University of Verona, AOUI Verona, Verona, Italy.
2. Department of Biochemistry, Federico II University, Naples, Italy.
3. Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
4. New York Blood Center, New York, New York.
5. Department of Cell, Development and Regenerative Biology, Icahn School of Medicine at Mount Sinai, New York, New York.
Abstract
Entities:
Mesh:
Animals
Autophagy
Doxorubicin/toxicity
Erythroblasts/enzymology
Erythropoiesis/drug effects
Erythropoiesis/genetics
Erythropoiesis/physiology
Female
Janus Kinase 2/metabolism
Mice
Mice, Knockout
NF-E2-Related Factor 2/metabolism
Oxidation-Reduction
Oxidative Stress/physiology
Phenylhydrazines/toxicity
Phosphorylation
Protein Processing, Post-Translational
Proto-Oncogene Proteins c-fyn/deficiency
Proto-Oncogene Proteins c-fyn/genetics
Proto-Oncogene Proteins c-fyn/physiology
Reactive Oxygen Species
Receptors, Erythropoietin/metabolism
STAT5 Transcription Factor/metabolism
Signal Transduction
Sirolimus/pharmacology
TOR Serine-Threonine Kinases/metabolism
Substances:
NF-E2-Related Factor 2
Nfe2l2 protein, mouse
Phenylhydrazines
Reactive Oxygen Species
Receptors, Erythropoietin
STAT5 Transcription Factor
phenylhydrazine
Doxorubicin
TOR Serine-Threonine Kinases
mTOR protein, mouse
Fyn protein, mouse
Jak2 protein, mouse
Janus Kinase 2
Proto-Oncogene Proteins c-fyn
Sirolimus
Year: 2018 PMID: 30252956 PMCID: PMC7213426 DOI: 10.1002/ajh.25295
Source DB: PubMed Journal: Am J Hematol ISSN: 0361-8609 Impact factor: 10.047